Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab for GVHD Prevention in Mismatched HCT
NCT00720629Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2007
- Primary completion
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of visilizumab in graft-versus-host disease (GVHD), sponsored by Moffitt Cancer Center. Started Dec 2007; status: terminated.
02
Drugs
visilizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00720629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00720629.